• METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC

  2026-05-29

  Wang et al. identified the METTL16-SENP3-LTF signaling axis as a critical regulator of ferroptosis resistance in hepatocellular carcinoma (HCC), revealing its role in promoting tumorigenesis. Their study highlights the potential of targeting this pathway to sensitize HCC cells to ferroptosis, offering new directions for therapeutic intervention.

• Gastroretentive Alfuzosin HCl Sponges: MRI-Validated Drug De

  2026-05-28

  This study developed and characterized low-density, gastroretentive sponges loaded with Alfuzosin HCl for enhanced oral bioavailability. By optimizing polymer composition and structure, the team achieved sustained drug release and validated prolonged gastric retention in healthy volunteers using MRI, offering a promising platform for targeted delivery in benign prostatic hyperplasia research.

• I-BET-762: BET Inhibitor Workflows for Ferroptosis & Inflamm

  2026-05-28

  I-BET-762 empowers researchers to precisely modulate BET-driven transcription, enabling advanced studies in ferroptosis sensitization and inflammatory gene regulation. This guide delivers practical workflows, troubleshooting insights, and evidence-based protocol parameters—bridging mechanistic findings with actionable strategies for both cancer and inflammation research.

• Hoechst 33258: Precision DNA Staining for Tumor pH Research

  2026-05-27

  Explore how Hoechst 33258, a bis-benzimide DNA stain, enables high-resolution DNA visualization in live and fixed cells, with unique advantages for tumor cell and microenvironment pH studies. This article connects mechanistic insights to practical applications, offering new perspectives beyond standard protocols.

• LY2886721 as a Precision BACE Inhibitor for Alzheimer’s Mode

  2026-05-27

  LY2886721 empowers Alzheimer’s research with nanomolar BACE1 inhibition, enabling targeted amyloid beta reduction while preserving synaptic function at moderate doses. This article translates bench data and real-world workflows into actionable protocols and troubleshooting strategies for maximizing reproducibility and insight in amyloid pathology studies.

• Novobiocin Sodium Inhibits Membrane and Vacuole Formation in

  2026-05-26

  This study demonstrates that Novobiocin Sodium, an aminocoumarin antibiotic, inhibits both membrane biosynthesis and vacuole formation in protoplasts of Enterococcus faecalis by blocking DNA replication. These findings clarify the dependence of bacterial protoplast enlargement on DNA replication and support the use of Novobiocin Sodium as a precise tool to dissect cell cycle dynamics in metabolic enzyme and antibiotic resistance research.

• Synthetic Viability in ERCC1-Deficient Lung Cancer Cells Exp

  2026-05-26

  Heyza et al. systematically dissect the interplay between ERCC1 deficiency, p53 status, and cellular response to interstrand crosslinking agents in lung cancer models. Their findings reveal how p53 mutation alters the hypersensitivity of ERCC1-deficient cells to platinum-based chemotherapy, challenging previous biomarker paradigms and highlighting new considerations for personalized cancer therapy.

• Computational Design Enables Rapid Biosensing of Amatoxins a

  2026-05-26

  This study introduces a computationally guided approach for designing haptens and monoclonal antibodies, resulting in a dual-target fluorescent assay for simultaneous detection of amatoxins and phallotoxins in mushrooms. The method addresses critical gaps in rapid, on-site identification of lethal mushroom toxins, with significant implications for public health and toxin research workflows.

• Translational Impact of YM-155 Hydrochloride in Cancer Model

  2026-05-25

  Explore the mechanistic depth and strategic guidance underpinning YM-155 hydrochloride, a potent and selective survivin inhibitor, in translational cancer research. This article integrates in vitro evaluation advances, competitive benchmarking, and workflow-centric protocols to empower researchers in optimizing apoptosis pathway targeting and maximizing preclinical rigor.

• Ademetionine (SAM): Mechanistic Leverage in CNS Translationa

  2026-05-24

  This thought-leadership article bridges mechanistic insight into S-adenosylmethionine (SAM, Ademetionine) with actionable strategy for translational researchers targeting neurological and psychiatric disorders. Integrating deep biochemistry, validated experimental protocols, and the evolving competitive landscape, it articulates how APExBIO's S-Adenosylmethionine product empowers next-generation translational workflows. The discussion uniquely synthesizes clinical context with emerging molecular data, differentiating itself from standard reagent guides.

• Norepinephrine:Angiotensin II Dose Ratios in Vasodilatory Sh

  2026-05-23

  This post-hoc analysis of the ARAMIS trial establishes a 10:1 conversion ratio (norepinephrine bitartrate:angiotensin II) for vasodilatory hypotension, a key metric for critical care research and practice. The study clarifies dose translation between vasopressors and informs protocol design, especially in the context of prior ARB exposure.

• Lyotropic Self-Assembly of Coil-Bottlebrush Diblocks in Ioni

  2026-05-22

  This study reveals that coil-bottlebrush diblock copolymers form diverse nanostructures in alkylimidazolium-based ionic liquids, with phase behavior showing weak dependence on ionic liquid structure. These findings expand fundamental understanding of lyotropic assembly, facilitating the design of advanced nanomaterials with tunable properties.

• Harnessing ML-7 Hydrochloride: Next-Gen MLCK Inhibition in T

  2026-05-22

  This thought-leadership article explores ML-7 hydrochloride as a potent and selective myosin light chain kinase (MLCK) inhibitor, offering mechanistic insights and actionable guidance for translational researchers in cardiovascular and vascular dysfunction models. By integrating recent evidence—including pivotal studies on MLCK-mediated phosphorylation, cytoskeletal regulation, and cell barrier integrity—this piece advances the discourse beyond conventional applications and highlights untapped opportunities for experimental design and biomarker discovery. Strategic perspectives are provided to maximize the translational impact of ML-7 hydrochloride, with a critical analysis of protocol parameters and an outlook on future innovation.

• E-64: Strategic Cysteine Protease Inhibition in Translation

  2026-05-21

  This thought-leadership article explores the mechanistic foundations and translational strategies for deploying E-64—a potent L-trans-epoxysuccinyl peptide cysteine protease inhibitor—in advanced biomedical research. Integrating insights from viral immunology, cancer research, and cell death pathways, we dissect the rationale for precise cysteine protease inhibition, highlight best practices for experimental design, and position E-64 as a uniquely validated tool for next-generation translational workflows. Drawing from recent literature and competitive guidance, this piece offers actionable protocols and a forward-looking vision for translational scientists.

• RepSox ALK5 Inhibitor: Advancing iPSC Platelet Differentiati

  2026-05-21

  RepSox, a potent and selective ALK5 inhibitor, is transforming induced pluripotent stem cell workflows by enabling efficient, cost-effective platelet differentiation. This article translates recent protocol innovations and troubleshooting strategies into actionable guidance for researchers in regenerative medicine and hematology.

459 records 17/31 page Previous Next First page 上5页 1617181920 下5页 Last page